画像診断の進歩とその評価

—低線量CT検診の場合—

抄録

It is difficult to evaluate whether to have to recommend a new modality as a periodical screening program, although increasing with the power of detection of tiny tumor by improving of diagnostic imaging. The randomized-controlled trial which to evaluate the efficacy of cancer screening as most importance approach, is necessary for the long period and every tens of thousands of participants. National Lung Screening Trial to evaluate low dose CT screening for lung cancer demonstrated 20% reduction of lung cancer mortality according to the study protocol. There is, however, no movement to recommend low dose CT screening as a national screening program for lung cancer, since 27percent of high diagnostic workup rate and high fatality of biopsy cases. It is necessary to plan epidemiological study to evaluate a new promising modality as possible as an early stage, because there is unequal between the diagnostic modality and medical evaluation for cancer screening.